Month: August 2024

CARGOTEC CORPORATION, HALF-YEAR FINANCIAL REPORT JANUARY–JUNE 2024, 8 AUGUST 2024 AT 9:00 AM (EEST) Cargotec’s half-year financial report January–June 2024: Sixth consecutive quarter with good results, demerger completedHiab’s strong profitability continued, comparable operating profit margin was 15.9% in the second quarter MacGregor’s comparable operating profit increased to EUR 21 million in the second quarter Sales process of MacGregor started Outlook specified for Hiab and MacGregorUnless otherwise stated, the financial information in this report concerns Cargotec’s continuing operations. April–June 2024 in brief: Orders received increasedOrders received increased by 4 percent and totalled EUR 584 (562) million. Order book amounted to EUR 1,691 (31 Dec 2023: 1,788) million at the end of the period. Sales decreased...

OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update. “We are very pleased today to announce that Ohtuvayre (ensifentrine) is now available in the US for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) in adults,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer. “Ohtuvayre is the first novel inhaled product available for the treatment...

Harvia Plc, Half-year financial review 8 August 2024 at 9:00 a.m. EESTHarvia Q2 2024: Significant sales growth and strong profitability This release is a summary of Harvia Plc’s Half-year financial review January–June 2024. The complete report is attached to this release as a pdf file. It is also available on Harvia’s website at https://harviagroup.com/.  Highlights of the review period April–June 2024:Revenue increased by 20.7% to EUR 43.2 million (35.8). At comparable exchange rates, revenue increased by 20.3% to EUR 43.0 million. Organic revenue growth was 20.1%. Operating profit was EUR 8.9 million (7.8), making up 20.7% (21.9%) of the revenue. Adjusted operating profit was EUR 9.4 million (8.0), making up 21.8% (22.3%) of the revenue. At comparable exchange rates, the adjusted operating profit was EUR 9.4 million (21.8% of the...

KALMAR CORPORATION, HALF-YEAR FINANCIAL REPORT JANUARY–JUNE 2024, 8 August 2024 AT 9:20 AM (EEST) Kalmar’s half-year financial report January–June 2024: Continued solid profitabilityDemerger of Cargotec and listing of Kalmar successfully completed Orders received totalled EUR 375 (437) million in the second quarter, demand sequentially on a stable level Order book at the end of June totalled EUR 925 (1,281) million Sales declined by 25 percent from the same quarter previous year and amounted to EUR 417 (552) million in the second quarter Share of eco portfolio1 sales represented 40 (33) percent of consolidated sales in the second quarter The comparable operating profit margin amounted to 12.6 (13.0) percent in the second quarter, presenting a solid profitability Kalmar’s reporting segments are Equipment and Services. Equipment’s...

HighlightsPower generation amounted to 456 GWh for the reporting period, representing an increase of more than 20 percent compared to 378 GWh in the same period in the previous year, and was around ten percent below expectations primarily as a result of weak wind speeds in the reporting period. Significantly strengthened balance sheet following the divestment of the Leikanger hydropower plant in April 2024 for MEUR 53, with proportionate net debt reduced to MEUR 46 and significant liquidity headroom available through the MEUR 170 revolving credit facility. Acquired a 500 MW portfolio of early-stage solar and battery projects from one of the largest landowners in Sweden, and continued to mature projects from the existing 40 GW pipeline towards the ready-to-permit milestone.Consolidated financials – 6 monthsCash flows from operating...

Q2 revenue and EBITDA are in line with expectations. We reconfirm our EBITDA guidance of DKK 600m for 2024. CEO Jens Andersen says:“Recovery is now taking root in Denmark. In Q2, Solar Danmark’s growth almost edged into positive territory, and we are now seeing signs of recovery. We are confident that this positive development will continue for the remainder of the year and in our other markets. We continue to initiate measures to mitigate the impact of cost inflation and market slowdown. Consequently, we reconfirm our EBITDA guidance of DKK 600m for 2024.” Q2 key financial messagesQ2 EBITDA is on par with expectations. Net working capital continued to improve. 2024 EBITDA guidance of DKK 600m reconfirmed.Financial highlights (DKK million) Q2 2024 Q2 2023 H1 2024 H1 2023Revenue 3,100 3,250 6,130 6,906EBITDA 137 214 225 494Cash...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets.  Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open to the public and encouraged, especially for those wishing to ask questions. Questions can be submitted at https://forms.gle/1LNMHJyWwUuH9sqJ8.About RecursionRecursion...